Your browser doesn't support javascript.
loading
Microarray patches enable the development of skin-targeted vaccines against COVID-19.
Korkmaz, Emrullah; Balmert, Stephen C; Sumpter, Tina L; Carey, Cara Donahue; Erdos, Geza; Falo, Louis D.
Afiliación
  • Korkmaz E; Department of Dermatology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA; Department of Bioengineering, Swanson School of Engineering, University of Pittsburgh, Pittsburgh, PA 15261, USA. Electronic address: ek001@pitt.edu.
  • Balmert SC; Department of Dermatology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA.
  • Sumpter TL; Department of Dermatology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA; Department of Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15261, USA.
  • Carey CD; Department of Dermatology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA.
  • Erdos G; Department of Dermatology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA.
  • Falo LD; Department of Dermatology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA; Department of Bioengineering, Swanson School of Engineering, University of Pittsburgh, Pittsburgh, PA 15261, USA; UPMC Hillman Cancer Center, Pittsburgh, PA 15232, USA; Clinical and Translational Scien
Adv Drug Deliv Rev ; 171: 164-186, 2021 04.
Article en En | MEDLINE | ID: mdl-33539853
The COVID-19 pandemic is a serious threat to global health and the global economy. The ongoing race to develop a safe and efficacious vaccine to prevent infection by SARS-CoV-2, the causative agent for COVID-19, highlights the importance of vaccination to combat infectious pathogens. The highly accessible cutaneous microenvironment is an ideal target for vaccination since the skin harbors a high density of antigen-presenting cells and immune accessory cells with broad innate immune functions. Microarray patches (MAPs) are an attractive intracutaneous biocargo delivery system that enables safe, reproducible, and controlled administration of vaccine components (antigens, with or without adjuvants) to defined skin microenvironments. This review describes the structure of the SARS-CoV-2 virus and relevant antigenic targets for vaccination, summarizes key concepts of skin immunobiology in the context of prophylactic immunization, and presents an overview of MAP-mediated cutaneous vaccine delivery. Concluding remarks on MAP-based skin immunization are provided to contribute to the rational development of safe and effective MAP-delivered vaccines against emerging infectious diseases, including COVID-19.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Piel / Parche Transdérmico / Desarrollo de Medicamentos / Vacunas contra la COVID-19 / SARS-CoV-2 / COVID-19 Límite: Humans Idioma: En Revista: Adv Drug Deliv Rev Asunto de la revista: FARMACOLOGIA / TERAPIA POR MEDICAMENTOS Año: 2021 Tipo del documento: Article Pais de publicación: Países Bajos

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Piel / Parche Transdérmico / Desarrollo de Medicamentos / Vacunas contra la COVID-19 / SARS-CoV-2 / COVID-19 Límite: Humans Idioma: En Revista: Adv Drug Deliv Rev Asunto de la revista: FARMACOLOGIA / TERAPIA POR MEDICAMENTOS Año: 2021 Tipo del documento: Article Pais de publicación: Países Bajos